Allergic Manifestation in Paediatric Patients with Primary Immunodeficiency Diseases
Keywords:immunodeficiencies, allergy, asthma, atopy, allergic manifestation
Introduction. Primary immunodeficiency diseases (PID) are a diverse group of rare genetic disorders that affect the development and/or function of the immune system. Affected individuals are predisposed to an increased rate and severity of infections, allergy, autoimmunity and malignancy. Primary immunodeficiency diseases are considered rare; physicians and general practitioners have little knowledge about the clinical presentation, diagnostic approach and health impact of PID. Many PID patients have a clinical history in favour of allergic diseases. Nevertheless, in these patients, the importance and prevalence of atopic disorders have not been completely explained.
Aim. The aim of this study was to evaluate atopic presentations, including atopic dermatitis, allergic rhinitis and asthma in a group of PID patients under the care of our clinic.
Material and Methods. Fifty-seven pediatric patients with PID primary immunodeficiency diseases were enrolled from March 2018 to April 2019. Serum IgE levels were measured. Information regarding the patient’s history of allergic diseases, including asthma, allergic rhinitis and atopic dermatitis were analysed.
Results and Conclusions. Confirmed allergy/asthma was found in 40 patients (70%). Thirty-eight patients (66.7%) had a diagnosis of asthma, 7 patients (12.3%) of allergic rhinitis and 13 (22.8%) of atopic dermatitis. Serum IgE total level was elevated in 12 patients (21%).
Immunodeficiency diseases (ID) involve a quantitative and/or functional disorder in the immune system  that can result in a greater susceptibility to infections, immunological disruption, autoimmunological dysregulation, inflammation and malignancy. If the origin is genetic, it is classified as primary immunodeficiency disorder (PID) and as secondary immunodeficiency disorder (SID) if acquired. To date, about 300 separate primary immunodeficiency disorders have been defined , in most cases they are antibody disorders (56.7%), other well defined PIDs (13.9%), phagocytic disorders (8.7%), T-cell deficiencies (7.5%) and complement deficiencies (4.9%) . An incidence of PID is estimated as 41–83/100.000 population, according to most studies .
There are reports about a probable correlation between some PID and allergic diseases, due to their common atopic presentations. A lot of patients affected by PID manifest a clinical history which may suggest an allergic asthma, allergic rhinitis or atopic dermatitis [5-8].
There is some data indicating that immunodeficiencies, for example, hyper-IgE syndrome and Wiskott–Aldrich syndrome, may have an atopic component. In other PID, mainly those considering antibody deficiencies, atopy is more prevalent than in normal population, however its role has not been fully revealed . Since patients with PID and allergic disease first present to a specialist with alike complaints, these two disease groups regularly take the same place in their differential diagnosis.
The aim of this study was to evaluate atopic presentations, including atopic dermatitis, allergic rhinitis and asthma in a group of PID patients.
Material and Methods
Study Design and Subjects
The study was conducted in the Department of Pediatrics and Allergy, Medical University of Lodz, Poland, from March 2018 to April 2019. Fifty-seven patients (38 males and 19 females) aged 4–18 years, with a diagnosis of primary immunodeficiencies who attended our department at that time, were enrolled in the study.
The diagnosis was established previously and the patients were evaluated due to the clinical and laboratory criteria of PID, according to the International Union of Immunological Societies (IUIS) Primary Immunodeficiency Diseases Classification Committee [6,9].
Data including age, history of asthma, allergic rhinitis and atopic dermatitis were collected from all patients by analysis of medical documentation and medical interviews. Total serum IgE levels and specific IgE level (against Dermatophagoidespteronyssinus, Dermatophagoidesfarinae, Cladosporium, Alternaria, cat and dog dander, Aspergillus, grass mix and tree mix) were measured (by using ImmunoCAP method) in all patients. Allergic rhinitis, atopic dermatitis and asthma diagnosis were defined according to international guidelines [10-12]. Diagnosis was confirmed by a specialist and documented.
Fifty-seven eligible patients (66% males and 33% females) were enrolled into the analysis. Within the study group, 20 patients (35%) suffered from hypogammaglobulinaemia, 31 patients (54%) had IgG subclass deficiency, 3 patients (5%) had common variable immunodeficiency, and 3 (5%) patients were diagnosed with agammaglobulinaemia (Figure 1).
Confirmed allergy/asthma was found in 40 patients (70%). The allergic evaluation revealed that 38 patients (66.7%) had a diagnosis of asthma, 13 patients (22.8%) had a clinical history of atopic dermatitis and 7 patients (12.3%) suffered from allergic rhinitis (Figure 2). Fifteen patients (26.3%) manifested at least two diseases amongst asthma, atopic dermatitis and allergic rhinitis, while 14 patients from the study group (24.6%) were diagnosed with three of diseases.
The IgE total level was elevated in 12 patients (21%) and specific IgE level was detected also in 12 patients (21%), while the presence of specific IgE level accompanied by elevated IgE total level was observed in 6 patients (10.5%) (Figure 3).
In this study, asthma was the most common (66.7%) atopic manifestation in PID patients; allergic rhinitis and atopic dermatitis were 12.3% and 22.8% respectively.
This study was carried out to extend our knowledge about atopies in children diagnosed with PID. Several studies have reported that the frequency of atopy and allergic disease may be higher in patients with PID  than the general population.
Allergic disorders and primary immunodeficiency may appear simultaneously. The large surface area of the respiratory, genitourinary, gastrointestinal system enable the potential invasion of pathogens. It is known that secretory IgA (its production may be insufficient in PID patients) acts an important role in the protection of the body through particular immune receptors and modulators. Secretory IgA also acts as a relevant antibody supervising allergic symptoms and limiting allergens to lamina propria, thus reducing the inflammatory response . Remittent infections may not only be with regard to immunodeficiency but also an allergic background has a significant role in clinical presentation [14,15]. In our population, 70% of patients with PID had allergic/asthma diseases.
Further studies have shown evidence linking antibody deficiency with asthma, which may indicate a higher prevalence of asthma in patients with PID than the normal population . Importantly the United States Immunodeficiency Network (USIDNET) imply that asthma, not bronchiectasis, is the most prevalent respiratory disorder among CVID patients . There are also data insinuating that some asthma affected patients may also suffer from underlying PID which might not be diagnosed . An impaired immune defence leading to remittent infections can cause a chronic inflammatory response, resulting in airway hyperreactivity, remodelling, and ultimately to fixed obstruction.
At the beginning of the infectious-inflammatory process, convertible changes might be clinically assessed as asthma . There are opinions that remittent sinopulmonary infections with regard to PID, which might be underdiagnosed, could be the cause of chronic inflammation, resulting in hyperreactivity, damages and remodelling . Identification of the role of PID as a participant in remittent infections and airway damage should refine the treatment of those potentially preventable forms of COPD.
There are reports of severe asthma in patients affected with high IgG subclass deficiency . In our population, asthma was confirmed in 66.7% of patients. Furthermore, a positive role of antibiotic usage in early childhood in the development of asthma and allergic diseases is discussed. The risk of asthma development may be increased in children who undergo more than four antibiotic therapies during their first year of life . From this perspective, many patients affected with PID could be at higher risk of developing asthma and allergy due to recurrent infections and frequent antibiotic courses during early childhood .
Allergic rhinitis is diagnosed on the basis of the patient’s symptoms and specific IgE detection. Taking in consideration the abnormalities in the production of immunoglobulin and especially that the majority of CVID affected individuals do not produce IgE , it is noticeable that the detection of specific IgE to aeroallergens, as a diagnostic standard for allergic rhinitis, might not be manageable. For that reason, CVID patients suspected of allergic rhinitis may require additional testing, for example, by nasal provocation with the most prevalent allergens . In our population, AR was diagnosed in 12.3% cases. A feasible illumination for the low detection of serum specific IgE in individuals affected CVID and allergic rhinitis can be their defective efficiency in producing immunoglobulins on a larger scale with continually present local specific IgE production to aeroallergens. According to some studies, the specific IgE local production in patients affected asthma or rhinitis was evaluated by detecting the transcription and mRNA expression of IgE in the local mucosa .
Approximately 50% of patients with PID show cutaneous manifestations. Skin infections are triggered frequently by Staphylococcus aureus and eczemas are the two most common ones. Eczematous dermatitis is one of the noninfectious skin manifestations in PID patients but is also commonly reported in the general population . Thus, it is significant to be aware that the single presence of particular skin lesions does not always indicate immunological disorders. On the other hand, there are also some reports indicating that dermal alterations predated and were the grounds for clinical immunological diagnosis . That is why the identification of precise skin symptoms in association with another clinical condition which may suggest immunity impairment and should point towards suspicion of underlying PID and consequently facilitate early recognition .
The frequent occurrence of allergies and asthma noticed in PID individuals may be considered as a result of an unstable equilibrium of the cellular and humoral immune system. The inclusion of reported atopic presentations in our study group may result in an over-estimation of its prevalence, but on the other hand, the overlapping of allergic disorders and immunodeficiency can be the reason for delayed recognition. The fact that pediatric patients with atopic disorders can present higher frequency and severity courses of infectious diseases is probable due to persistent inflammation in the airways and skin. Thus, manifestations descending from an impaired immune system may be recognised as part of the atopic disorder and vice versa .
Evaluation of atopy in PID patients is a challenge. Respiratory symptoms might be both a presentation of infectious complications or an allergic reaction of the respiratory tract. Moreover, PID, particularly CIVD, are often diagnosed belatedly [15,25]. A considerable cause of this situation might be the insufficient knowledge of PID amongst paediatricians, besides those in specialised centres. Contrarily, the high prevalence of remittent minor infections in children with an unaffected immune system and the significance of clinical overlapping with atopic disorders make it extremely difficult to establish a proper diagnosis. Paediatric patients who manifest atopic or autoimmune diseases and remittent infections should have at least their immunoglobulin levels evaluated to ensure exact treatment as quickly as possible. On a final note, it will minimalise the risk related to severe infection and improve the quality of life patients with chronic infectious diseases . In summary, Atopic manifestations, including asthma, allergic rhinitis and eczema should be evaluated in patients with PID.
How to Cite
Copyright (c) 2020 Joanna Pawłowska, Agnieszka Sobocińska, Izabela Kałuzińska-Parzyszek, Joanna Jerzyńska, Agnieszka Brzozowska
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.